376 related articles for article (PubMed ID: 19915350)
1. [Hematopoietic stem cell transplantation for multiple myeloma].
Kanda Y
Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
[No Abstract] [Full Text] [Related]
2. [New treatment strategies for multiple myeloma].
Ozaki S
Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
[No Abstract] [Full Text] [Related]
3. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
5. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Lemaire O; Attal M; Bourin P; Laroche M
Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
[No Abstract] [Full Text] [Related]
6. [Chemotherapy for multiple myeloma].
Ishida T
Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of transplant-eligible symptomatic multiple myeloma].
Nakaseko C
Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
[No Abstract] [Full Text] [Related]
9. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Chim CS; Choi PT; Lee WK
Ann Hematol; 2013 Jun; 92(6):855-7. PubMed ID: 23183880
[No Abstract] [Full Text] [Related]
10. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Dasanu CA; Reale MA; Bauer F
Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
[No Abstract] [Full Text] [Related]
12. [Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Tsurumi H
Rinsho Ketsueki; 2014 Oct; 55(10):2027-35. PubMed ID: 25297768
[No Abstract] [Full Text] [Related]
13. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
[TBL] [Abstract][Full Text] [Related]
14. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
15. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
Braiteh F; Hymes SR; Giralt SA; Jones R
J Clin Oncol; 2008 Sep; 26(27):4511-3. PubMed ID: 18802165
[No Abstract] [Full Text] [Related]
16. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
17. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Rajkumar SV
Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
[No Abstract] [Full Text] [Related]
18. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
[No Abstract] [Full Text] [Related]
19. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD; Lechowicz MJ; Khoury HJ; Flowers CR; Waller EK
Clin Cancer Res; 2010 Oct; 16(20):5079-86. PubMed ID: 20739431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
